[P63] ポスターセッション 63　呼吸器（周術期）

[P63-5] Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR-mutated resectable NSCLC: NeoADAURA

^○谷田部 恭¹, 坪井 正博², Weder Walter³, Escriu Carles⁴, Blakely Collin⁵, He Jianxing⁶, Dacic Sanja⁷, Sanja Lingmin⁸, Walding Andrew⁹, Andrew Jamie¹⁰ (1.国立がん研究センター 中央病院 病理診断科, 2.国立がん研究センター 東病院, 3.Thoraxchirurgie, Klinik Bethanien, Switzerland, 4.The Clatterbridge Cancer Centre, United Kingdom, 5.University of California, United States, 6.The First Affiliated Hospital of Guangzhou Medical University, China, 7.University of Pittsburgh Medical Center, United States, 8.AstraZeneca, United States, 9.AstraZeneca, United Kingdom, 10.Memorial Sloan Kettering Cancer Center, United States)